adr_usa_0503|ASLN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
adr_usa_0503|ASLN|1|ASLAN Pharmaceuticals Ltd Total Current Assets (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Cash and Short Term Investments (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Inventories (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net PP&E (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Goodwill and Intangibles (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Current Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Long Term Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Deposits (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Book Value (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Retained Earnings (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Treasury Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd EV to Revenues|ASLAN Pharmaceuticals Ltd EV to Earnings|ASLAN Pharmaceuticals Ltd EV to Free Cash Flow|ASLAN Pharmaceuticals Ltd EV to Assets (Quarterly)|ASLAN Pharmaceuticals Ltd PS Ratio|ASLAN Pharmaceuticals Ltd PE Ratio|ASLAN Pharmaceuticals Ltd Price to Book Value|ASLAN Pharmaceuticals Ltd PEG Ratio|ASLAN Pharmaceuticals Ltd Debt to Equity Ratio|ASLAN Pharmaceuticals Ltd Dividend Yield|ASLAN Pharmaceuticals Ltd Shareholder Yield (TTM)|ASLAN Pharmaceuticals Ltd Percent of Shares Outstanding Short|ASLAN Pharmaceuticals Ltd Total Receivables (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Payables (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Capital Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Return on Invested Capital|ASLAN Pharmaceuticals Ltd Quality Ratio Score|ASLAN Pharmaceuticals Ltd Momentum Score|ASLAN Pharmaceuticals Ltd Beta (1Y)|ASLAN Pharmaceuticals Ltd Sustainable Growth Rate (TTM)|ASLAN Pharmaceuticals Ltd Institutional Investor Ownership Percentage|ASLAN Pharmaceuticals Ltd Average Diluted Shares Outstanding (Quarterly)|ASLAN Pharmaceuticals Ltd Total Employees (Annual)|ASLAN Pharmaceuticals Ltd EPS Diluted (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd SG&A Expense (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Shares Outstanding|ASLAN Pharmaceuticals Ltd Repurchase of Capital Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Ordinary Shares Number (Quarterly)|ASLAN Pharmaceuticals Ltd Payout Ratio|ASLAN Pharmaceuticals Ltd Quick Ratio (Quarterly)|ASLAN Pharmaceuticals Ltd Normalized Diluted EPS (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Stock Buybacks (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Effective Tax Rate (TTM)|ASLAN Pharmaceuticals Ltd Return on Equity|ASLAN Pharmaceuticals Ltd Net Income (TTM) (USD)|ASLAN Pharmaceuticals Ltd Revenue (TTM) (USD)|ASLAN Pharmaceuticals Ltd Dividend Per Share (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Revenue (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Gross Profit (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Pre-Tax Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net Interest Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Price (USD)|ASLAN Pharmaceuticals Ltd Total Return Price (USD)|ASLAN Pharmaceuticals Ltd Enterprise Value (USD)|ASLAN Pharmaceuticals Ltd 30-Day Average Daily Volume|ASLAN Pharmaceuticals Ltd 1 Year Price Returns (Daily)|ASLAN Pharmaceuticals Ltd Short Interest|ASLAN Pharmaceuticals Ltd PE Ratio (Forward)|ASLAN Pharmaceuticals Ltd PE Ratio (Forward 1y)|ASLAN Pharmaceuticals Ltd PS Ratio (Forward)|ASLAN Pharmaceuticals Ltd PS Ratio (Forward 1y)|ASLAN Pharmaceuticals Ltd Quarterly EPS Estimates (USD)|ASLAN Pharmaceuticals Ltd Quarterly Revenue Estimates (USD)|ASLAN Pharmaceuticals Ltd Quarterly EPS Surprise|ASLAN Pharmaceuticals Ltd Quarterly Revenue Surprise|ASLAN Pharmaceuticals Ltd Quarterly Actual EPS (USD)|ASLAN Pharmaceuticals Ltd Quarterly Actual Revenue (USD)|ASLAN Pharmaceuticals Ltd Revenue Estimates for Current Fiscal Year (USD)|ASLAN Pharmaceuticals Ltd Revenue Estimates for Next Fiscal Year (USD)|ASLAN Pharmaceuticals Ltd Price Target (USD)|ASLAN Pharmaceuticals Ltd Consensus Recommendation|ASLAN Pharmaceuticals Ltd Price Target Num Estimates|ASLAN Pharmaceuticals Ltd EPS Estimates for Current Fiscal Year (USD)|ASLAN Pharmaceuticals Ltd EPS Estimates for Next Fiscal Year (USD)|ASLAN Pharmaceuticals Ltd Research and Development Expense (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Reconciled Depreciation (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Non-Operating Interest Expense (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Land and Improvements (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Buildings and Improvements (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Other Properties (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Machine, Furniture & Equipment (Quarterly) (USD)||
adr_usa_0503|ASLN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
adr_usa_0503|ASLN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|daily|daily|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
adr_usa_0503|ASLN|5|96.3333333333|96.3333333333||96.3333333333|96.3333333333|96.3333333333|96.3333333333|96.3333333333||96.3333333333|96.3333333333|||91.3846153846|7|92|||6.9648241206|1.43373493976|91.25|1.44979079498|91.3333333333|15.2471910112|96.5882352941|96.3333333333|96.3333333333|91.2857142857||31.5333333333|30.5|91.5|30.5|91.3181818182|511.4|91.3181818182|91.3181818182|53.2142857143||96.3333333333|91.25|91.25|91.3181818182|91.4|91.4|91.5|91.2631578947|||91.2727272727|91.3846153846|91.3181818182|91.3181818182|91.3181818182|7|7|7|7|6.97945205479|15.2471910112|||||91.3333333333|91.3333333333|91.2857142857||91.2857142857|91.2857142857|21|27.9803921569|31.7142857143|13.4545454545|31.7142857143|28.5384615385|39|91.3181818182|91.3684210526|91.3181818182||100.4|96.3333333333|99.6363636364||
adr_usa_0503|ASLN|6|18|18||18|18|18|18|18||18|18|||13|198|2|||199|166|8|956|3|89|17|18|18|7||30|32|6|14|22|5|22|22|28||18|8|8|22|10|10|6|19|||11|13|22|22|22|198|198|198|192|146|89|||||12|12|7||7|7|53|51|42|99|42|39|33|22|19|22||10|18|11||
adr_usa_0503|ASLN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
adr_usa_0503|ASLN|201312|||||||||||||||||||||||||||||||||||10|||||||||||||||||||||||||||||||||||||||||||||||||||
adr_usa_0503|ASLN|201412|||||||||||||||||||||||||||||||||||19|||||||||||||||||||||||||||||||||||||||||||||||||||
adr_usa_0503|ASLN|201512|||||||||||||||||||||||||||||||||||25|||||||||||||||||||||||||||||||||||||||||||||||||||
adr_usa_0503|ASLN|201603||||||||||||||||||||||||||||||||||18.5153||-0.2143|1.4963||||||-0.2143|||||||||-3.9685|-3.9685|-0.1645||||||||||||||||||||||||1.9409|0.0131|0.1645||||||
adr_usa_0503|ASLN|201606||||||||||||||||||||||||||||||||||19.3216||-0.1732|1.2206||||||-0.1818|-8.8518||||||0.2539||-3.3456|-3.3456|-0.1492||||||||||||||||||||||||2.3782|0.0142|0.1492||||||
adr_usa_0503|ASLN|201609||||||||||||||||||||||||||||||||||23.1218||0.2277|1.9312||||||0.2327|-14.2562||||||10.3238||5.2638|5.2638|-0.0648||||||||||||||||||||||||2.897|0.016|0.1113||||||
adr_usa_0503|ASLN|201612|52.9351|51.5563||0.3831|0.084|12.0968|3.7903|8.3065||41.4297|-48.224||||||||||0.2005||||1.2895|3.7903|35.6266|||||||26.0152||-0.2603|2.2234|||130.1289||13.9425|-0.2796|0.8842|||-8.8209|||0.9617||-6.7706|-6.7706|-0.0965||||||||||||||||||||||||5.8154|0.0326|0.0014|||0.3831|||
adr_usa_0503|ASLN|201703|45.987|45.8305||0.3619|0.0816|12.9474|4.2249|8.7225||33.6694|-59.8947||||||||||0.2591|||||4.2249|38.1367|||||||23.127||-0.3577|2.0183|||130.1289||10.8477|-0.3577||||-13.1255|||||-8.2731|-8.2731|-0.1027||||||||||||||||||||||||5.9673|0.0418|0.1027|||0.3619|||
adr_usa_0503|ASLN|201706|69.8183|69.7515||0.5306|0.079|12.8169|3.858|8.9589||57.7876|-68.9835||||||||||0.155|||||3.858|42.8254|-35.8352||||-42.8433||24.303||-0.3785|1.917|26.0258||130.1289||18.0795|-0.3785|-32.7947||-42.8433|-18.9777|||||-9.1978|-9.1978|-0.1029||||||||||||||||||||||||6.9984|0.0533|0.1029|||0.5306|||
adr_usa_0503|ASLN|201709|60.6525|60.5768||0.4892|0.0852|11.6074|2.383|9.2244||49.7828|-76.8409||||||||||0.1841|||||2.383|42.7864|-59.061||||-70.4262||26.0415||-0.3041|2.2278|26.0258||130.1289||25.4203|-0.3041|0.0299||-70.4262|-32.1618|||||-7.9203|-7.9203|0.0672||||||||||||||||||||||||5.6005|0.0574|0.105|||0.4892|||
adr_usa_0503|ASLN|201712|50.6452|50.5732||0.4436|0.0841|15.8203|5.9788|9.8415||35.5134|-90.2833||||||||||0.2726|||||5.9788|41.514|-75.8952||||-91.4896||26.0832||-0.5643|2.6951|26.0258||130.1289||8.4587|-0.5643|-0.2962||-91.4896|-39.923|||||-14.5318|-14.5318|-0.0203||||||||||||||||||0.7632||||||11.7454|0.0575|0.1064|||0.0352|0.2113||
adr_usa_0503|ASLN|201803|28.6391|28.5556||0.4141|23.1019|25.3599|14.9374|10.4224||26.9564|-104.4428||||-2.7359||||5.8122|-0.0288|0.3705|||0.0578||14.9374|44.8684|-80.8092||||-99.2601||26.0152||-0.3379|3.2978|26.0258||130.1289||1.9117|-0.3379|||-99.2601|-40.4405|||||-8.7906|-8.7906|-0.1129|6.02|6.02|138.1078|||15053||||||||||||9.9723|12|2|4||-1.425|5.178|0.0587|0.1129|||0.4141|||
adr_usa_0503|ASLN|201806|44.9464|44.7493||0.3682|22.9796|15.8714|5.7162|10.1552||52.6137|-109.7874|||-5.911|-3.6434|3.6497|||8.5928|-0.0496|0.1838||-14.5619|0.0182||5.7162|52.3301|-78.2741||||-94.9591||29.5862||-0.35|3.0641|32.0258||160.129||7.8285|-0.35|-41.0496||-94.9591|-42.286|||||-11.0336|-11.0434|-0.0399|7.78|7.78|213.0621|105078.2||4745||||||||||||9.9392|12.25|2|4||-1.04|8.3225|0.0551|0.1122|||0.3682||8.06|7.9
adr_usa_0503|ASLN|201809|34.9282|34.7897||0.3364|23.0751|16.9381|6.7252|10.2129||41.7659|-121.5055|||-5.0619|-3.4898|3.9308|||4.8574|-0.1418|0.2344||-16.6728|0.0026||6.7252|52.6065|-89.4127||||-110.3087||32.0947||-0.3496|2.7559|32.0498||160.2489||5.173|-0.3496|-1.1304||-110.3087|-45.5867|||||-11.2162|-11.2209|-0.004|7.7067|7.7067|220.488|3190.5333||826||||||||||||9.214|12|2|4||-1.45|8.681|0.0653|0.1094|||0.3364||6.045|5.09
adr_usa_0503|ASLN|201812|29.0925|28.9089||0.2884|23.0806|22.2628|7.9984|14.2644||30.618|-132.4689|||-2.3776|-1.1827|1.8995|||2.3865|-0.0838|0.4564||-37.3917|0.0047||7.948|51.6272|-87.8058||||-112.6776||32.0729|56|-0.35|1.9007|32.0498||160.2489||3.6143|-0.3511|||-112.6776|-42.2467|||||-11.1918|-11.1918|-0.1299|3.11|3.11|74.6732|19048.7667||1515|||||||||||11.4955|11.5258|7.375|2|4|-1.355|-1.1133|9.204|0.0626|0.1585|||0.0362|0.2769|3.65|3.12
adr_usa_0503|ASLN|201903||||||||||||||-3.2422|-1.9593||||4.4905||||-29.2705|0.0038||||-77.3894|||2.1226|||32.0498||-0.15|2.2564|32.0498|||||-0.15||-0.046||-37.8001|||3|2.9|-4.3411|-4.344|-0.1307|4.2899|4.2899|122.5563|25820.9667|-43.8538|1222|||||||||||18.2271|23.0892|7.625|2|4|-1.03|-0.8467|4.4495||0.1997|||||3.882|3.38
adr_usa_0503|ASLN|201906|15.1947|15.0501||0.9611|23.0782|21.2054|5.9763|15.2291||18.4197|-144.7439|||-2.5825|-1.5443||||3.6427|||||0.2311||5.737|51.6272|||2|2.1093|||32.0498||-0.25|1.8854|32.0498||160.2489|||-0.25||-1.4024||-34.6878|||||-7.4589|-7.931|-0.127|3.48|3.48|96.5992|23053.8|-59.954|74068|||||||||||17.2845|17.0623|7.625|2|4|-0.7067|-0.76|5.2886||0.2022||0.862|0.0991||2.92|1.51
adr_usa_0503|ASLN|201909|8.1366|7.9935||0.8506|23.0772|19.1973|4.3224|14.8749||13.1913|-149.929|||-1.63|-0.9252||||3.1842|||||0.1187||3.8206|51.6272|||1|2.4645|||32.0498||-0.15|1.1117|32.0498||160.2489|||-0.15||-1.3989||-28.652|||||-5.2649|-5.1852|-0.2064|1.83|1.83|57.8761|33153.4|-75.9211|38038|||||||||||3.0022|9.2533|7.75|2|4|-0.685|-0.66|4.1458|0.1043|0.2066||0.7944|0.0353|0.2146|1.7|2.32
adr_usa_0503|ASLN|201912|22.272|22.203||0.7662|0.0028|23.9528|5.3832|18.5695||-1.6774|-179.4848|||-1.9477|-1.177||||5.8464|||||2.8318||4.7257|61.3668|||3|3.3078|||33.7647|23|-0.9|3.2582|37.991||189.955|||-0.3257||-0.8745||-47.016||||0.0177|-29.5927|-29.5558|-0.2869|2.26|2.26|73.6243|2992319|-27.3312|1075813|||||-0.16||-462.5||-0.9||3.005|17.9922|5.6667|2.5|3|-0.685||2.7026|0.0849|0.2931||0.8827|0.0353|0.2113|2.04|1.94
adr_usa_0503|ASLN|202003|17.0797|16.8943||0.6909|0.0019|21.9237|3.8208|18.1029||-4.7591|-182.5315|||-1.0592|-0.64|||||||||0.0518||3.5527|61.3668|||2|3.2574|||37.991||-0.1|0.9975|||189.955|||-0.1||-0.8893||-45.7186|||||-3.2338|-3.0467|-0.3389|1.165|1.165|40.0366|181720.7333|-72.069|19676|||||-0.12||16.6667||-0.1|||1.6655|5|2.5|3|-0.58|-0.67|2.3546||0.339||0.6612|0.0297||1.6826|1.7589
adr_usa_0503|ASLN|202006|14.1226|13.8274||0.6172|0.0009|22.9648|4.3692|18.5956||-8.7576|-186.4907|||-2.1333|-1.2892|||||||||0.0738||3.5309|61.3668|||3|4.2558|||37.991||-0.1|1.7909|37.991||189.955|||-0.1||0.1588||-41.7468|||||-4.0878|-3.9592|-0.3385|2.1943|2.1943|80.6406|122622.7333|-36.9454|28034|||||-0.1||||-0.1|||1.6636|5.5|2.3333|2|-0.43|-0.69|1.8926||0.3386||0.595|0.0353|0.2085|1.6|1.53
adr_usa_0503|ASLN|202009|12.4148|12.0603||0.5487|0.0004|24.8166|6.2211|18.5955||-12.0428|-189.7519|||-2.0824|-1.2302|||||||||0.6315|0.0126|4.3261|61.3668|||5|2.8106||9.0473|37.991||-0.1|1.3475|37.991||189.955|||-0.1||0.5335||-40.0377|||||-3.9751|-3.476|-0.2433|1.77|1.77|76.9517|66218.9333|-3.2787|239908|||||-0.0467||-114.2704||-0.1|||1.692|5.5|2.3333|2|-0.255|-0.395|2.1853|0.074|0.2435||0.5288|0.0353|0.2136|1.64|1.88
adr_usa_0503|ASLN|202012|15.5023|14.4623||0.4759|0.0002|26.234|10.6575|15.5766||-10.453|-195.6827|||-2.4213|-1.2159|||||||||0.0278|0.5288|5.8645|61.8262|||1|2.1247||13.2945|39.8082|18|-0.15|3.0333|47.5327||237.6633|||-0.15||||-16.1979|||||-5.6746|-5.716|-0.326|1.92|1.92|76.0562|470873.1|-11.1111|13216|||||-0.05||-200||-0.15||||5.5|2.3333|2|-0.1833||2.8816|0.0728|0.3262||0.8827|0.0353|0.2049|2.5|3.41
adr_usa_0503|ASLN|202103|101.7443|100.8183||0.4045||21.047|5.5555|15.4915||81.1208|-202.4032|||-3.8949|-3.553||||2.8967|||||1.8958|0.5288|5.3939|63.0089|||8|0.6853||43.4688|51.4327||-0.15|3.1051|69.5209||347.6046|||-0.15||||-19.8717|||||-6.9702|-6.7205|-0.4113|3.25|3.25|249.0454|4005901.1333|211.9658|1318009|||||-0.065||-100||-0.13||1.6661||8.5|2.3333|2|-0.22|-0.6|3.751||0.4115||0.3963|0.0082||3.38|2.87
adr_usa_0503|ASLN|202106|94.7354|94.1202||0.3388|0.012|20.6701|5.1197|15.5503||75.3548|-207.8323|||-3.9902|-2.3759||||2.8881|||||2.1848||4.6672|63.0136|||7|-1.4122||51.7436|69.7614||-0.05|3.7888|69.6172||348.0861|||-0.05||||-21.3415|||||-5.4483|-5.429|-0.2034|3.37|3.37|159.7398|440452.2333|66.5094|1520974|||||-0.08||-39.025||-0.1112||||8|2|3|-0.2975|-0.37|4.0445||0.2034||0.3301|0.0087||2.7|2.67
adr_usa_0503|ASLN|202109|101.9283|100.5036||0.2842|0.011|36.9543|6.141|30.8133||67.8999|-216.4282|||-1.4366|-0.8977||||1.7923|||||1.7013||5.7947|63.02|||8|1.4325||36.5547|69.6634||-0.1|2.7685|||348.0861|||-0.1||-0.8663||-26.42|||||-8.5545|-8.5545|-0.4981|1.94|1.94|54.3025|1367758.1333|-6.3158|1184422|||||-0.12||||-0.12||||8|2|3|-0.3467|-0.4033|5.2617||0.4981||0.2639|0.0202||1.52|1.44
adr_usa_0503|ASLN|202112|||||||||||||||-0.1447||||1.1586|||||0.1356||||||3|1.0953||36.2568||||||||||||||||||||||1.13|1.13|10.4436|358696.1667|-41.0256|94383|||||-0.145||||||||8|2|3|-0.48|-0.55||||||||0.89|0.9
adr_usa_0503|ASLN|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.16|||||||||||||||||||||
adr_usa_0503|ASLN|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.17|||||||||||||||||||||
adr_usa_0503|ASLN|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.17|||||||||||||||||||||
adr_usa_0503|ASLN|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.18|||||||||||||||||||||